Angiex, Inc.

Meet The Scientist Behind Angiex's Cancer Breakthrough

About this Event

Angiex is on a path to making cancer a non-lethal disease. Their lead product, AGX101, has the potential to transform cancer treatment.

AGX101 is based on a special biology discovered by the founder of Angiex, Shou-Ching Jaminet. It is a protein called TM4SF1 that is necessary for the growth of tumor blood vessels and for the invasion or metastasis of tumor cells. AGX101 is a novel Antibody-Drug Conjugate (ADC) that targets cancer lethality through three distinct mechanisms of action:

  • Attacking Tumor Blood Vessels: By destroying the blood vessels that supply tumors without harming normal blood vessels, AGX101 shrinks tumors to minimal size.
  • Activating Anti-Tumor Immunity: AGX101 enhances the body’s immune response against cancer, increasing the likelihood of complete responses to therapy.
  • Killing Invasive and Metastatic Tumor Cells: Killing these cells may eliminate cancer’s ability to invade or metastasize – processes thought to account for 90% of cancer deaths.

AGX101 has the largest preclinical therapeutic margin ever seen in an oncology drug, indicating potential for unprecedented safety. It is a true “magic bullet,” delivering a ten-fold higher fraction of injected drug to the tumor than other ADCs. Phase 1 clinical trials are currently underway, with encouraging early results.

Watch this Fireside Chat with Angiex co-founder and CEO, Paul Jaminet, along with founder and Scientific Advisor, Shou-Ching Jaminet, as they discuss how Angiex is on mission to make cancer a non-lethal disease and a path to make that happen.

Video On Demand

– Recorded

January 28

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.